- TRANSCRIPT: Mayoral Candidate Alleges Mayor, Council "Embarassed" by Towing Outcry; Council Allegedly Persecutes Disabled Member for Backing Ordinance
- Marshall School of Medicine establishes new dentistry department
- Law Enforcement Across North Carolina Comes Out in Favor of Syringe Exchange
- Marshall’s dean of CITE receives Outstanding Civil Engineering Educator of the Year for 2015
- Non-Profit launched to promote medical cannabis reform
- Detroit drug dealer sentenced to Federal prison for heroin crime
- Reps. Jenkins and Clark Introduce Opiod Prescribing Bill
- AT&T Announces Nearly 60 Jobs Available in Huntington
- Greenbrier County man pleads guilty to Federal crime involving oxycodone
- Huntington YMCA‘s Free Healthy Kids Day® on April 30th Aims to Help Kids Exercise Minds and Bodies
Biomedical sciences researcher to present results of clinical trials on personalized chemotherapy
Thursday, June 12, 2014 - 03:21 Updated 1 year ago Special to HNN Provided by Marshall University
He will be discussing the results of clinical trials conducted at the Edwards Comprehensive Cancer Center. The studies tested ChemoID, a cell culture method he developed with colleague Dr. Jagan Valluri to measure the sensitivity of patients' tumors to chemotherapy treatment for lung, brain/spine and breast cancer.
He says more evaluation of the technology is needed, but preliminary tests on a small number of patients found ChemoID 100 percent accurate in predicting which drug is more effective in treating patients affected by brain cancer if the tumor-initiating cancer stem cells were evaluated.
"Oncologists every day face many challenges in determining the best course of therapy for an individual cancer patient," says Claudio. "The basic problem is that patients with similar diagnoses don't always respond to the same chemotherapy. This technology we have developed could help physicians select the appropriate chemotherapy for an individual patient giving them an edge in the fight against cancer."
He says the good news for cancer patients is that ChemoID may make possible personalized treatment by predicting the most effective drug combination to successfully target that specific patient's cancer increasing the chance the drugs will work and perhaps reducing side effects by helping the patient avoid unnecessary drugs.
In addition to presenting his own research at the conference, Claudio will be moderating a session, "Advances in Oncology and Anticancer Research. Cancer Pathology."
Summaries of the research presented at the meeting will be published in the journal Frontiers in Bioscience.